Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07211139
What this trial is testing

Head and Neck Advanced Research for Multi-Omics and Optimized Immunotherapy

Who this might be right for
Head and Neck Cancer
Samsung Medical Center 30
Not applicableStudy completedNCT02940639
What this trial is testing

Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

Who this might be right for
Renal Cell Carcinoma
Bristol-Myers Squibb 499
Early research (Phase 1)Study completedNCT02916095
What this trial is testing

Kanitinib in Treating Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd. 9
Large-scale testing (Phase 3)UnknownNCT02031939
What this trial is testing

Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Who this might be right for
Advanced Rectal Cancer
Sun Yat-sen University 556
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07420439
What this trial is testing

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Who this might be right for
Non Small Cell Lung Cancer MetastaticInterstitial Lung Disease (ILD)
Intergroupe Francophone de Cancerologie Thoracique 108
Testing effectiveness (Phase 2)WithdrawnNCT03190239
What this trial is testing

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Xinqiao Hospital of Chongqing
Testing effectiveness (Phase 2)Study completedNCT00275951
What this trial is testing

Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
National Taiwan University Hospital 39
Not applicableLooking for participantsNCT04595929
What this trial is testing

Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-

Who this might be right for
Peritoneal CarcinomatosisGastric Cancer
St. Petersburg State Pavlov Medical University 304
Early research (Phase 1)Ended earlyNCT00369629
What this trial is testing

Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome

Who this might be right for
Lymphoma
Northwestern University 14
Early research (Phase 1)Looking for participantsNCT06062745
What this trial is testing

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Who this might be right for
Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma
Brigham and Women's Hospital 30
Not applicableStudy completedNCT01666145
What this trial is testing

Advanced Image Guidance Utilized in Liver Surgery

Who this might be right for
Carcinoma, Hepatocellular
Wake Forest University Health Sciences 14
Large-scale testing (Phase 3)UnknownNCT05429684
What this trial is testing

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Who this might be right for
HER2+ Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University 120
Early research (Phase 1)Study completedNCT02182206
What this trial is testing

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Who this might be right for
Tumors
Boehringer Ingelheim 50
Not applicableStudy completedNCT04670445
What this trial is testing

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

Who this might be right for
Stage IV MelanomaAdvanced Lung CancerStage IV Non-Small Cell Lung Cancer+19 more
Massachusetts General Hospital 199
Not applicableUnknownNCT04646772
What this trial is testing

Surgery for Locally Advanced Colon Cancer: is it Worth it? A Multicenter Retrospective Analysis.

Who this might be right for
Malignant Neoplasm of Large Intestine TNM Staging Primary Tumor (T) T4
Santo Spirito Hospital, Italy 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04395677
What this trial is testing

AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Who this might be right for
Non Small Cell Lung Cancer
Nuvation Bio Inc. 173
Testing effectiveness (Phase 2)UnknownNCT04803851
What this trial is testing

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Who this might be right for
AnlotinibAnti-PD-1 AntibodyAdvanced Pancreatic Cancer
Peking Union Medical College Hospital 29
Testing effectiveness (Phase 2)Ended earlyNCT00373204
What this trial is testing

Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Who this might be right for
Lung Cancer
Pharmacyclics LLC. 50
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Early research (Phase 1)Study completedNCT02273388
What this trial is testing

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

Who this might be right for
Neoplasms
Boehringer Ingelheim 65
Next Page